Check-Cap Files Firm Commitment Offering to Finance MBody AI Merger
MBAI sits 85% above its 52-week low of $0.593 on light trading volume (0.1× avg).
Summary
Check-Cap Ltd. has filed for a firm commitment public offering to fund its pending merger with MBody AI and support the combined company's robotics and AI platform development. The offering size and price are yet to be determined, but the filing underscores the company's urgent need for financing given its going-concern status.
Key Events · Financing and Capital Events · MBAI
-
Firm Commitment Public Offering Filed
An F-1 registration statement has been filed for a firm commitment public offering of ordinary shares, with Northland Securities acting as sole bookrunner. The number of shares and price range are not yet determined, but the assumed offering price may come at a discount to the July 23, 2026 closing price of $1.17.
-
Proceeds to Fund Merger and MBody AI Operations
Net proceeds are allocated as follows: roughly 10% for Merger transaction costs, 50% to acquire and deploy third-party robotic systems, 10% for inventory, 20% for development of the MBody AI Orchestrator platform, and 10% for working capital.
-
Merger Outside Date Extended to December 31, 2026
A letter agreement dated June 22, 2026 extended the Merger Agreement's outside date from June 30, 2026 to December 31, 2026, and removed the condition that no MBody Material Adverse Effect has occurred.
-
Existing Equity Line Provides Pricing Context
Under an existing $30 million equity line with ARC Group International Ltd., the company sold 683,000 shares at an average price of $1.49 for approximately $1.0 million in gross proceeds as of July 23, 2026.
Analysis · MBAI · Industrial Applications And Services
To fund its reverse merger with MBody AI, clinical-stage diagnostics company Check-Cap has filed for a firm commitment public offering. While the deal size remains unpriced, the filing signals a potential discount to the current $1.17 share price. Proceeds are primarily earmarked for deploying MBody AI's robotic systems and advancing its AI platform. This capital raise is critical for closing the merger—now extended to year-end 2026—and for sustaining the combined company's operations. The offering is dilutive, but with a going-concern warning and only $219,000 in cash as of December 2025, external financing is essential. The filing also discloses an existing $30 million equity line, under which shares have been sold at an average of $1.49, offering a pricing benchmark.
At the time of this filing, MBAI was trading at $1.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $0.59 to $3.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.